Welcome to Fresenius Kabi Oncology Limited Website. As we move ahead in our journey to become a global leader in Oncology, I am delighted to introduce Fresenius Kabi Oncology Limited as our new company name. This newly named organization is now a part of the €16.0 billion Fresenius Group, headquartered in Germany. In-house research capabilities and infrastructure are being strengthened further by our integration with Fresenius Kabi, a business segment of Fresenius group.

Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in most important countries of Latin America and Asia Pacific. We are happy to inform you that now you can expect "Total Cancer Care" for the patients from the Fresenius Kabi Group through its market presence in cytotoxics, enteral and parenteral nutrition, transfusion technology and infusions. We assure more in our deliverables for critically and chronically ill patients.

Through our vision "To become the world leader in oncology generics" and our mission of "Caring for life", we remain committed to newer opportunities based on innovation and entrepreneurship. Bringing pharmaceutical expertise along with the best minds in the business, we are committed to work continuously to raise the bar on "Total Cancer Care".

We owe our success to our esteemed healthcare professionals, stakeholders and academia for their trust and unflinching support and also, to our numerous employees who have committed themselves to the cause of a better life for people suffering from cancer.

Our quest for excellence will continue as we grow in strength and stature, constantly working to create value for our stakeholders, investors, customers and employees.



Peter Folke Nilsson
Managing Director & CEO